These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19106164)

  • 41. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE; Bochkova AG; Bunchuk NV
    Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis.
    Radovits BJ; Fransen J; Eijsbouts A; van Riel PL; Laan RF
    Rheumatology (Oxford); 2009 Aug; 48(8):906-10. PubMed ID: 19478038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel predictor of clinical response to methotrexate in patients with rheumatoid arthritis: a pilot study of in vitro T cell cytokine suppression.
    Haroon N; Srivastava R; Misra R; Aggarwal A
    J Rheumatol; 2008 Jun; 35(6):975-8. PubMed ID: 18464312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.
    Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
    J Rheumatol; 2006 Mar; 33(3):481-5. PubMed ID: 16463431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective.
    Jois RN; Leeder J; Gibb A; Gaffney K; Macgregor A; Somerville M; Scott DG
    Rheumatology (Oxford); 2006 Dec; 45(12):1566-9. PubMed ID: 16705043
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
    Helliwell PS; Taylor WJ;
    J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
    Popa C; Leandro MJ; Cambridge G; Edwards JC
    Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup.
    Keeling S; Oswald A; Russell AS; Maksymowych WP
    J Rheumatol; 2006 Mar; 33(3):558-61. PubMed ID: 16463437
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate?
    Lacaille D; Stein HB; Raboud J; Klinkhoff AV
    J Rheumatol; 2000 Aug; 27(8):1922-7. PubMed ID: 10955334
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.
    Glintborg B; Gudbjornsson B; Krogh NS; Omerovic E; Manilo N; Holland-Fischer M; Lindegaard HM; Loft AG; Nordin H; Johnsen L; Oeftiger SF; Hansen A; Rasmussen C; Grondal G; Geirsson AJ; Hetland ML
    Rheumatology (Oxford); 2014 Nov; 53(11):2100-9. PubMed ID: 24939677
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.
    Burge DJ; Bookbinder SA; Kivitz AJ; Fleischmann RM; Shu C; Bannink J
    Clin Ther; 2008 Oct; 30(10):1806-16. PubMed ID: 19014836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis.
    Yazici Y; Krasnokutsky S; Barnes JP; Hines PL; Wang J; Rosenblatt L
    J Rheumatol; 2009 May; 36(5):907-13. PubMed ID: 19332636
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
    van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Ewals JA; Han KH; Hazes JM; Kerstens PJ; Peeters AJ; van Zeben D; Breedveld FC; Huizinga TW; Dijkmans BA; Allaart CF
    Arthritis Rheum; 2009 Jan; 61(1):4-12. PubMed ID: 19116965
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.
    Albers HM; Wessels JA; van der Straaten RJ; Brinkman DM; Suijlekom-Smit LW; Kamphuis SS; Girschick HJ; Wouters C; Schilham MW; le Cessie S; Huizinga TW; Ten Cate R; Guchelaar HJ
    Arthritis Rheum; 2009 Jan; 61(1):46-51. PubMed ID: 19116975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment.
    Laas K; Peltomaa R; Kautiainen H; Puolakka K; Leirisalo-Repo M
    Ann Rheum Dis; 2006 Jul; 65(7):924-8. PubMed ID: 16339293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study.
    Lopez-Gonzalez R; Loza E; Jover JA; Benitez Del Castillo JM; Mendez R; Hernandez-Garcia C; Pato E
    Scand J Rheumatol; 2009; 38(1):58-62. PubMed ID: 18991187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis.
    Takeuchi T; Tatsuki Y; Nogami Y; Ishiguro N; Tanaka Y; Yamanaka H; Kamatani N; Harigai M; Ryu J; Inoue K; Kondo H; Inokuma S; Ochi T; Koike T
    Ann Rheum Dis; 2008 Feb; 67(2):189-94. PubMed ID: 17644554
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.
    Gonzalez-Juanatey C; Llorca J; Vazquez-Rodriguez TR; Diaz-Varela N; Garcia-Quiroga H; Gonzalez-Gay MA
    Arthritis Rheum; 2008 Dec; 59(12):1821-4. PubMed ID: 19035415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
    Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
    J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.